Immunotherapy for Alzheimer’s disease:targetingβ-amyloid and beyond
作者机构：Department of Pharmacology and Chemical BiologyShanghai Jiao Tong University School of MedicineShanghai 200025China Shanghai Universities Collaborative Innovation Center for Translational MedicineShanghai Jiao Tong University School of MedicineShanghai 200025China Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of EducationShanghai Jiao Tong University School of MedicineShanghai 200025China Academy of Integrative MedicineShanghai University of Traditional Chinese MedicineShanghai 201203China Department of Clinical PharmacyInstitute of Interdisciplinary Integrative Medicine ResearchShuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 201203China.
出 版 物：《Translational Neurodegeneration》 (转化神经变性病（英文）)
年 卷 期：2022年第11卷第1期
页 面：690-706页
核心收录：
学科分类：1002[医学-临床医学] 100203[医学-老年医学] 10[医学]
基 金：the National Natural Science Foundation of China(81973297,82073836,81872841 and 82003719) Key Project of Shanghai Science and Technology Commission(19JC1413100) Research Foundation of Translational Medicine of Shanghai Jiao Tong University(ZH2018ZDA23)
主 题：Alzheimer’s disease Immunotherapy Vaccine Antibody Drug development
摘 要：Alzheimer’s disease(AD)is the most common neurodegenerative disease in the elderly ***,the complexity of AD pathogenesis leads to discrepancies in the understanding of this disease,and may be the main reason for the failure of AD drug ***,many ongoing preclinical and clinical studies will continually open up avenues to unravel disease mechanisms and guide strategies for AD diagnosis and drug *** example,immunotherapeutic strategies targeting amyloid-β(Aβ)and tau proteins were once deemed almost certainly effective in clinical treatment due to the excellent preclinical ***,the repeated failures of clinical trials on vaccines and humanized anti-Aβand anti-tau monoclonal antibodies have resulted in doubts on this ***,a new anti-Aβmonoclonal antibody(Aducanumab)has been approved by the US Food and Drug Administration,which brings us back to the realization that immunotherapy strategies targeting Aβmay be still ***,immunotherapies based on other targets such as tau,microglia and gut-brain axis are also under *** research is still needed to clarify the forms and epitopes of targeted proteins to improve the accuracy and effectiveness of immunotherapeutic *** this review,we focus on the immunotherapies based on Aβ,tau and microglia and their mechanisms of action in *** addition,we present up-to-date advances and future perspectives on immunotherapeutic strategies for AD.
维普期刊数据库